Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego
California
92131
United States
Website: http://www.fatetherapeutics.com/
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
134 articles with Fate Therapeutics, Inc.
-
Fate Therapeutics to Present at Upcoming May Investor Conferences
5/6/2022
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
5/4/2022
Fate Therapeutics, Inc. reported business highlights and financial results for the first quarter ended March 31, 2022.
-
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results
4/22/2022
Fate Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Wednesday, May 4, 2022 at 5:00 PM ET to report its first quarter 2022 financial results and provide a corporate update.
-
Fate Therapeutics to Present at Upcoming March 2022 Investor Conferences
3/2/2022
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
2/28/2022
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
2/16/2022
Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update.
-
Fate Therapeutics to Present at Upcoming February 2022 Investor Conferences
2/2/2022
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
1/10/2022
Fate Therapeutics, Inc. (NASDAQ: FATE), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
-
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
12/13/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), today showcased positive interim Phase 1 data from the Company’s FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
-
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
12/13/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual Meeting and Exposition.
-
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
12/8/2021
Fate Therapeutics, Inc. announced that management will host a virtual event entitled “B -cell Lymphoma Franchise Update” on Tuesday, December 14, 2021 at 8:00 AM ET.
-
Fate Therapeutics to Present at Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
11/9/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), today announced that the Society for Immunotherapy of Cancer (SITC) Communications Committee selected an abstract featuring preclinical data from the Company’s FT538 and FT573 programs for showcase at the SITC 2021 Annual Meeting Press Conference.
-
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
11/4/2021
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, reported business highlights and financial results for the third quarter ended September 30, 2021.
-
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
11/4/2021
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced that three oral and five poster presentations for the Company’s induced pluripotent stem cell product platform were accepted for presentation at the 63rd American Society of Hematology Annual Meeting and Exposition being held from December 11-14, 2021.
-
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
10/25/2021
Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, November 4, 2021 at 5:00 p.m. ET to report its third quarter 2021 financial results and provide a corporate update.
-
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
10/1/2021
Fate Therapeutics, Inc. (NASDAQ: FATE), today announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021.
-
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
9/15/2021
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells.